University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without customization. However, some NK companies, such as Fate Therapeutics and Cytovia ...

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue - called induced pluripotent stem cells (iPSCs) - to make therapeutic CAR-NK cells.

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

University of Queensland research using "natural killer" cells may lead to the first new treatment for a devastating ...

A group of scientists in China has revealed a novel mechanism whereby a short form of IL-18, generated by caspase-3 cleavage ...